ORIGIO a/s, a listed medtech company on the Oslo 
Stock Exchange (OSE: ORO) has issued its second 
quarter report for 2011. The Q2 report is available 
on ORIGIO's website (www.origio.com), and through the 
Oslo Børs Information System. 

Financial highlights, Q2 2011
· Revenue in Q2 2011 of DKK 91.8 million which is 16% 
higher than Q2 2010. Revenue YTD of DKK 184.2 million 
or 21% higher than 2010
· EBITDA before special items increased in Q2 2011 to 
DKK 15.3 million (16.7% of revenue) and DKK 31.5 
million YTD (17.1% of revenue)
· Operating cash flow of DKK 6.5 million in Q2 2011 
vs. DKK 3.8 million in Q2 2010. YTD operating cash 
flow amounted to DKK 7.3 million, which is DKK 6.8 
million higher than 2010


Selected Strategic and Operational Highlights
· Organic growth of 20% in constant currency in Q2 
2011 and 22% YTD
· Acquisition of minority stake of MDT Artworks B.V 
(effect from July 6) - a Dutch manufacturer of IVF 
oocyte retrieval needles and embryo transfer 
catheters 
· Launch of the novel IVF medium, EmbryoGen® in July 
2011. CE-mark received in August 2011
· EmbryoSure; need for further investigation of the 
analysis method before human study can commence
· New promising data from hyaluronan based sperm 
screening (HBA®) and selection (PICSI®) study 


Revised Financial Guidance 2011 
Based on the results for the first half of 2011 and 
the outlook for the remaining year, the FY 2011 
guidance for sales, organic growth and EBITDA% before 
special items has been modified as per below. The new 
guidance includes the effect from MDT Artworks and 
EmbryoGen® with a total of DKK 9 million in revenue.

Revenue: DKK ~360 million, incl. constant currency 
organic growth of ~15%

EBITDA% before special items: 13-16%

Capital expenditures: DKK 10 - 15 million

Cash flow from operations: More than DKK 25 million

(The guidance is based on average FY USD/DKK rate of: 
5.33)